<DOC>
	<DOCNO>NCT02948608</DOCNO>
	<brief_summary>The objective study investigate extra-articular manifestation , pain mechanism , patient-reported outcome , comorbidities association condition patient spondyloarthropathy ( SpA ) treat Biologics . Further , assess predictive value baseline pain profile treatment outcome ≥ 3 month .</brief_summary>
	<brief_title>Clinical Characteristics Importance Outcome Patients With Spondyloarthritis</brief_title>
	<detailed_description>Patients spondyloarthropaty , initiate switch biologics routine care due active disease state , enrol observational study . The overall aim investigate extra-articular manifestation , pain mechanisms patient-reported outcome elucidate factor - independently interaction - influence treatment response ≥ 3 month . Patients baseline visit , eye examination follow visit ≥ 3 month . Clinical examination perform time point include : 1 . Clinical examination ( spinal movement ) 2 . Assessment pain mechanisms clinical evaluation ( BASDAI , tender point , ) pain questionnaire ( PainDETECT ) . 3 . The SPARCC Enthesitis Index use enthesitis count . 4 . Interview questionnaires regard lifestyle , comorbidity , function quality life 5 . Blood sample 6 . Urine sample 7 . Stool sample Clinical well patient-reported observer-based outcome describe overall study population prognostic influence extra-articular manifestation , comorbidity pain mechanism analyse .</detailed_description>
	<mesh_term>Spondylarthropathies</mesh_term>
	<mesh_term>Spondylarthritis</mesh_term>
	<criteria>Patients diagnose SpA ≥18 year age time consent Ability willingness give write informed consent meet requirement protocol Patients must history active disease BASDAI &gt; 40 ( 10100 ) elevate Creactive protein , despite current previous NSAIDs therapy Age &lt; 18 year No consent Pregnancy Active latent TB Diagnosed Human immunodeficiency virus Diagnosed hepatitis Current past malignant disease Recurrent chronic infection ( viral , fungal bacterial ) Multiple sclerosis Heart failure ( NYHA class III/IV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>spondyloarthropathy</keyword>
	<keyword>ankylose spondylitis</keyword>
	<keyword>spinal disease</keyword>
	<keyword>spondylitis</keyword>
	<keyword>spondylarthritis</keyword>
	<keyword>psoriasis</keyword>
	<keyword>uveitis</keyword>
	<keyword>joint disease</keyword>
</DOC>